News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
657,557 Results
Type
Article (32638)
Company Profile (642)
Press Release (624276)
Multimedia
Podcasts (63)
Webinars (16)
Section
Business (198259)
Career Advice (2108)
Deals (36518)
Drug Delivery (103)
Drug Development (78202)
Employer Resources (163)
FDA (15406)
Job Trends (14661)
News (334430)
Policy (29053)
Tag
Academia (1259)
Academic (1)
Accelerated approval (10)
Adcomms (16)
Allergies (96)
Alliances (47676)
ALS (113)
Alzheimer's disease (1364)
Antibody-drug conjugate (ADC) (169)
Approvals (15396)
Artificial intelligence (306)
Autoimmune disease (36)
Automation (15)
Bankruptcy (376)
Best Places to Work (10828)
BIOSECURE Act (22)
Biosimilars (115)
Biotechnology (437)
Bladder cancer (90)
Brain cancer (30)
Breast cancer (334)
Cancer (2701)
Cardiovascular disease (204)
Career advice (1741)
Career pathing (32)
CAR-T (182)
CDC (16)
Cell therapy (503)
Cervical cancer (20)
Clinical research (64987)
Collaboration (1026)
Company closure (3)
Compensation (683)
Complete response letters (30)
COVID-19 (2213)
CRISPR (56)
C-suite (345)
Cystic fibrosis (111)
Data (2884)
Decentralized trials (2)
Denatured (4)
Depression (69)
Diabetes (315)
Diagnostics (6359)
Digital health (23)
Diversity (4)
Diversity, equity & inclusion (38)
Drug discovery (132)
Drug pricing (123)
Drug shortages (27)
Duchenne muscular dystrophy (118)
Earnings (84320)
Editorial (39)
Employer branding (24)
Employer resources (141)
Events (111147)
Executive appointments (874)
FDA (16976)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (910)
Gene editing (131)
Generative AI (27)
Gene therapy (374)
GLP-1 (787)
Government (2934)
Grass and pollen (6)
Guidances (173)
Healthcare (15886)
HIV (37)
Huntington's disease (30)
IgA nephropathy (42)
Immunology and inflammation (163)
Immuno-oncology (9)
Indications (39)
Infectious disease (2379)
Inflammatory bowel disease (146)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (120)
Interviews (425)
IPO (17300)
IRA (45)
Job creations (4241)
Job search strategy (1441)
Kidney cancer (12)
Labor market (50)
Layoffs (567)
Leadership (20)
Legal (7323)
Liver cancer (75)
Longevity (11)
Lung cancer (384)
Lymphoma (188)
Machine learning (8)
Management (58)
Manufacturing (404)
MASH (90)
Medical device (13620)
Medtech (13625)
Mergers & acquisitions (19942)
Metabolic disorders (816)
Multiple sclerosis (99)
NASH (18)
Neurodegenerative disease (124)
Neuropsychiatric disorders (37)
Neuroscience (2058)
NextGen: Class of 2025 (5959)
Non-profit (1879)
Now hiring (48)
Obesity (419)
Opinion (259)
Ovarian cancer (93)
Pain (110)
Pancreatic cancer (119)
Parkinson's disease (186)
Partnered (20)
Patents (302)
Patient recruitment (163)
Peanut (52)
People (57172)
Pharmaceutical (132)
Pharmacy benefit managers (20)
Phase I (20427)
Phase II (28996)
Phase III (21511)
Pipeline (1634)
Policy (189)
Postmarket research (1961)
Preclinical (8255)
Press Release (64)
Prostate cancer (135)
Psychedelics (40)
Radiopharmaceuticals (270)
Rare diseases (465)
Real estate (5774)
Recruiting (65)
Regulatory (21111)
Reports (39)
Research institute (1290)
Resumes & cover letters (331)
Rett syndrome (9)
RNA editing (8)
RSV (48)
Schizophrenia (94)
Series A (165)
Series B (118)
Service/supplier (26)
Sickle cell disease (60)
Special edition (20)
Spinal muscular atrophy (147)
Sponsored (24)
Startups (3901)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (62)
The Weekly (58)
Vaccines (726)
Venture capital (56)
Weight loss (263)
Women's health (33)
Worklife (19)
Date
Today (82)
Last 7 days (374)
Last 30 days (1867)
Last 365 days (31146)
2025 (16770)
2024 (35586)
2023 (40307)
2022 (50705)
2021 (54005)
2020 (50918)
2019 (41844)
2018 (31980)
2017 (32466)
2016 (30616)
2015 (36068)
2014 (28902)
2013 (23906)
2012 (25494)
2011 (25659)
2010 (23634)
Location
Africa (674)
Alabama (69)
Alaska (6)
Arizona (171)
Arkansas (11)
Asia (42501)
Australia (6780)
California (7479)
Canada (2332)
China (698)
Colorado (320)
Connecticut (326)
Delaware (190)
Europe (88938)
Florida (1067)
Georgia (244)
Hawaii (2)
Idaho (56)
Illinois (552)
India (29)
Indiana (370)
Iowa (18)
Japan (226)
Kansas (103)
Kentucky (29)
Louisiana (13)
Maine (68)
Maryland (883)
Massachusetts (5725)
Michigan (259)
Minnesota (452)
Mississippi (3)
Missouri (88)
Montana (30)
Nebraska (22)
Nevada (75)
New Hampshire (69)
New Jersey (2096)
New Mexico (30)
New York (2058)
North Carolina (1165)
North Dakota (8)
Northern California (3280)
Ohio (218)
Oklahoma (12)
Oregon (40)
Pennsylvania (1574)
Puerto Rico (17)
Rhode Island (38)
South America (1065)
South Carolina (34)
South Dakota (1)
Southern California (2723)
Tennessee (98)
Texas (1105)
United States (27419)
Utah (211)
Virginia (182)
Washington D.C. (68)
Washington State (648)
West Virginia (4)
Wisconsin (67)
657,557 Results for "daiichi sankyo company ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO
May 23, 2025
·
12 min read
Lung cancer
Merck, Daiichi Sankyo Pull Lung Cancer Filing for ADC, Citing Underwhelming Survival Findings
Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations.
May 29, 2025
·
2 min read
·
Tristan Manalac
Cancer
AstraZeneca/Daiichi Sankyo, BioNTech, Merus to Present Promising Cancer Therapies at ESMO Asia 2024
At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus will reveal promising mid-stage data for their respective cancer candidates.
December 2, 2024
·
4 min read
·
Tristan Manalac
Policy
Arbitration Dispute Between Daiichi Sankyo and Seagen Ends
A dispute between Daiichi Sankyo Co., Ltd. (TSE: 4568) and Seagen Inc. is now concluded and Seagen has paid Daiichi Sankyo approximately U.S. $47 million in connection with attorneys’ fees and costs plus interest awarded by the arbitrator of the party’s dispute.
June 28, 2024
·
1 min read
Business
RevolKa Signed Master Service Agreement with Daiichi Sankyo
RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform signed a master service agreement with Daiichi Sankyo Co., Ltd.
May 27, 2024
·
2 min read
Breast cancer
AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data
Analysts at Leerink Partners said in a Monday note that DESTINY-Breast09’s findings “could support an approval” for Enhertu in first-line HER2+ metastatic breast cancer.
April 22, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Wayfinder Biosciences and Daiichi Sankyo collaborate to develop novel RNA-targeting therapies for neurodegenerative disease
April 15, 2025
·
2 min read
Antibody-drug conjugate (ADC)
AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers.
March 4, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
January 31, 2025
·
3 min read
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
1 of 65,756
Next
